128 related articles for article (PubMed ID: 11576836)
21. Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands.
Kruijtzer CMF ; Verweij J; Schellens JH; Beijnen JH; Pronk L; Bo M; Lustig V; van Tinteren H; Mackay M; Ten Bokkel Huinink WW
Anticancer Drugs; 2000 Apr; 11(4):249-55. PubMed ID: 10898539
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study.
Kunitoh H; Watanabe K; Onoshi T; Furuse K; Niitani H; Taguchi T
J Clin Oncol; 1996 May; 14(5):1649-55. PubMed ID: 8622084
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II trial.
Hesketh PJ; Crowley JJ; Burris HA; Williamson SK; Balcerzak SP; Peereboom D; Goodwin JW; Gross HM; Moore DF; Livingston RB; Gandara DR
Cancer J Sci Am; 1999; 5(4):237-41. PubMed ID: 10439170
[TBL] [Abstract][Full Text] [Related]
24. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
Sinibaldi VJ; Carducci MA; Moore-Cooper S; Laufer M; Zahurak M; Eisenberger MA
Cancer; 2002 Mar; 94(5):1457-65. PubMed ID: 11920502
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of weekly docetaxel in patients with metastatic breast cancer.
Aihara T; Kim Y; Takatsuka Y
Ann Oncol; 2002 Feb; 13(2):286-92. PubMed ID: 11886007
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial.
Pectasides D; Visvikis A; Aspropotamitis A; Halikia A; Karvounis N; Dimitriadis M; Athanassiou A
Eur J Cancer; 2000 Jan; 36(1):74-9. PubMed ID: 10741298
[TBL] [Abstract][Full Text] [Related]
27. A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer.
Kosmas C; Tsavaris NB; Makatsoris T; Onyenadum A; Vadiaka M; Stavroyianni N; Sepsas E; Dimitropoulos D; Rokana S; Kalofonos HP
Int J Cancer; 2002 Mar; 98(1):141-7. PubMed ID: 11857398
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer.
Miller VA; Rigas JR; Francis PA; Grant SC; Pisters KM; Venkatraman ES; Woolley K; Heelan RT; Kris MG
Cancer; 1995 Feb; 75(4):968-72. PubMed ID: 7842417
[TBL] [Abstract][Full Text] [Related]
29. Docetaxel: an active drug for squamous cell carcinoma of the head and neck.
Dreyfuss AI; Clark JR; Norris CM; Rossi RM; Lucarini JW; Busse PM; Poulin MD; Thornhill L; Costello R; Posner MR
J Clin Oncol; 1996 May; 14(5):1672-8. PubMed ID: 8622087
[TBL] [Abstract][Full Text] [Related]
30. Phase II trial of docetaxel for cholangiocarcinoma.
Pazdur R; Royce ME; Rodriguez GI; Rinaldi DA; Patt YZ; Hoff PM; Burris HA
Am J Clin Oncol; 1999 Feb; 22(1):78-81. PubMed ID: 10025387
[TBL] [Abstract][Full Text] [Related]
31. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.
Piccart MJ; Klijn J; Paridaens R; Nooij M; Mauriac L; Coleman R; Bontenbal M; Awada A; Selleslags J; Van Vreckem A; Van Glabbeke M
J Clin Oncol; 1997 Sep; 15(9):3149-55. PubMed ID: 9294478
[TBL] [Abstract][Full Text] [Related]
32. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
Chan S
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
[TBL] [Abstract][Full Text] [Related]
33. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study.
Rose PG; Blessing JA; Ball HG; Hoffman J; Warshal D; DeGeest K; Moore DH
Gynecol Oncol; 2003 Feb; 88(2):130-5. PubMed ID: 12586591
[TBL] [Abstract][Full Text] [Related]
34. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.
Valero V; Jones SE; Von Hoff DD; Booser DJ; Mennel RG; Ravdin PM; Holmes FA; Rahman Z; Schottstaedt MW; Erban JK; Esparza-Guerra L; Earhart RH; Hortobagyi GN; Burris HA
J Clin Oncol; 1998 Oct; 16(10):3362-8. PubMed ID: 9779713
[TBL] [Abstract][Full Text] [Related]
35. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
[TBL] [Abstract][Full Text] [Related]
36. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients.
de Wit R; Kruit WH; Stoter G; de Boer M; Kerger J; Verweij J
Br J Cancer; 1998 Nov; 78(10):1342-5. PubMed ID: 9823976
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
Valero V; Holmes FA; Walters RS; Theriault RL; Esparza L; Fraschini G; Fonseca GA; Bellet RE; Buzdar AU; Hortobagyi GN
J Clin Oncol; 1995 Dec; 13(12):2886-94. PubMed ID: 8523051
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study.
Katsumata N; Noda K; Nozawa S; Kitagawa R; Nishimura R; Yamaguchi S; Aoki D; Susumu N; Kuramoto H; Jobo T; Ueki K; Ueki M; Kohno I; Fujiwara K; Sohda Y; Eguchi F
Br J Cancer; 2005 Oct; 93(9):999-1004. PubMed ID: 16234823
[TBL] [Abstract][Full Text] [Related]
39. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial.
Hainsworth JD; Burris HA; Yardley DA; Bradof JE; Grimaldi M; Kalman LA; Sullivan T; Baker M; Erland JB; Greco FA
J Clin Oncol; 2001 Aug; 19(15):3500-5. PubMed ID: 11481356
[TBL] [Abstract][Full Text] [Related]
40. Single-agent docetaxel in metastatic breast cancer patients pre-treated with anthracyclines and paclitaxel: partial cross-resistance between paclitaxel and docetaxel.
Lin YC; Chang HK; Wang CH; Chen JS; Liaw CC
Anticancer Drugs; 2000 Sep; 11(8):617-21. PubMed ID: 11081452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
